
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under Rule 14a-12

Pieris Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- 1) Title of each class of securities to which transaction applies:
- 2) Aggregate number of securities to which transaction applies:
- 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- 4) Proposed maximum aggregate value of transaction:
- 5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:
- 1) Amount previously paid:
- 2) Form, Schedule or Registration Statement No:
- 3) Filing party:
- 4) Date Filed:
-

PIERIS PHARMACEUTICALS, INC.
255 State St, 9th Floor
Boston, MA 02109

REGARDING THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 23, 2020

This Notice of Change of Location relates to the proxy statement of Pieris Pharmaceuticals, Inc. (the "Company"), dated April 28, 2020, filed with the Securities and Exchange Commission and previously furnished to stockholders of the Company in connection with solicitation of proxies by the Board of Directors of the Company for use at the 2020 annual meeting of stockholders (the "Annual Meeting"), to be held on June 23, 2020.

On June 8, 2020, the Company issued a press release announcing that the Annual Meeting will be changed from an in-person meeting to a virtual-only meeting format. A copy of the press release is attached.

Except as specifically stated in this supplement, the information set forth in the proxy statement remains unchanged. We urge you to read this supplement carefully in its entirety together with the proxy statement. From and after the date of this supplement, all references to the "proxy statement" are to the proxy statement as supplemented herein. This supplement is being filed with the Securities and Exchange Commission and is being made available to stockholders on June 8, 2020.

THE NOTICE SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.



Pieris Pharmaceuticals Announces Virtual 2020 Annual Meeting of Stockholders

BOSTON, MA / ACCESSWIRE / June 8, 2020/ Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, announced today that due to the public health impact of the COVID-19 pandemic and to support the health and well-being of its stockholders, the 2020 Annual Meeting, scheduled for June 23, 2020 at 8:00 am Eastern Time, will be held in a virtual format only. An in-person meeting will not be held this year.

To attend and participate in the Annual Meeting, stockholders of record as of the close of business on April 24, 2020 may visit www.virtualshareholdermeeting.com/PIRS2020 and use the 16-digit control number received in their proxy notice to log into this website. Stockholders will have the opportunity to vote and ask questions during the Annual Meeting by following the instructions available on the meeting website. For stockholders who have already voted, no action is required. Stockholders may log into the website 15 minutes prior to the meeting start time.

A support line will also be available during the Annual Meeting should stockholders require assistance. Digital copies of the Company's proxy statement and 2019 Annual Report are available on the Company's website at www.pieris.com, and will also be available on the webcast.

Whether or not stockholders plan to attend the Annual Meeting, Pieris urges stockholders to select one of the methods described in the proxy materials to vote and submit their proxies in advance of the Annual Meeting. The proxy card included with the proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote stockholder shares in connection with the Annual Meeting.

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immune-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.

Forward-Looking Statements

Statements contained herein that relate to the Company's 2020 annual meeting of stockholders are forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words or phrases such as "will be," "will," "may" or other similar words or expressions often identify forward-looking statements. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, many of which are beyond our control. Among the factors that could cause the Company's 2020 annual meeting logistical arrangements to change include: general business and economic conditions; imposition of restrictive governmental regulations implemented to address public health concerns; or operational delays or difficulties because of the novel coronavirus or similar diseases, or uncertainty regarding the same. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Pieris Investor Relations Contact

Maria Kelman
Director of Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/593154/Pieris-Pharmaceuticals-Announces-Virtual-2020-Annual-Meeting-of-Stockholders>



NOTICE OF CHANGE OF LOCATION OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 23, 2020

Dear Stockholders,

Due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, and to protect the health and well-being of our stockholders, notice is hereby given that the location of the 2020 Annual Meeting of Pieris Pharmaceuticals, Inc. has been changed to a virtual-only format. The Annual Meeting will be held on June 23, 2020 at 8:00 am Eastern Time.

As described in the proxy materials for the Annual Meeting that were previously distributed, only stockholders of record at the close of business on April 24, 2020 are entitled to attend and participate at the Annual Meeting. You will be able to participate in the Annual Meeting, vote your shares and submit questions electronically during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/PIRS2020 and entering your 16-digit control number found in your proxy notice. If you encounter any difficulties accessing the live webcast on the day of the Annual Meeting, please call the technical support number provided on the website.

Whether or not you plan to participate in the live webcast of the Annual Meeting, we urge you to vote and submit your proxy in advance of the meeting by one of the methods described in the proxy materials for the Annual Meeting. The proxy card included with the proxy materials will not be updated to reflect the change in location and may continue to be used to vote your shares in connection with the Annual Meeting.

Sincerely,

A handwritten signature in black ink, appearing to read "S.S. Yoder", is written over a light blue horizontal line.

Stephen S. Yoder
President & Chief Executive Officer
Boston, Massachusetts
June 8, 2020